Screening of primary gp120 immunogens to formulate the next generation polyvalent DNA prime-protein boost HIV-1 vaccines
Our previous preclinical studies and a Phase I clinical trial DP6-001 have indicated that a polyvalent Env formulation was able to elicit broadly reactive antibody responses including low titer neutralizing antibody responses against viral isolates of subtypes A, B, C and AE. In the current report,...
Saved in:
Main Authors: | , , , , , , , , , , , , , |
---|---|
格式: | 图书 |
出版: |
Taylor & Francis Group,
2017-12-01T00:00:00Z.
|
主题: | |
在线阅读: | Connect to this object online. |
标签: |
添加标签
没有标签, 成为第一个标记此记录!
|
因特网
Connect to this object online.3rd Floor Main Library
索引号: |
A1234.567 |
---|---|
复印件 1 | 可用 |